Inogen Inc has announced the resignation of Kevin R.M. Smith from his roles as a director and officer of the company, effective November 16, 2026. This development is significant as it alters the leadership landscape of the company, which specializes in orthopedic, prosthetic, and surgical appliances and supplies.

Smith's departure follows a previous report on November 5, 2026, where it was noted that his role as an officer and employee ended on October 30, 2026. The resignation was not due to any disagreements regarding the company’s operations or policies, indicating a smooth transition.

Inogen Inc, traded under the ticker INGN on the Nasdaq, is based in Beverly, Massachusetts. The company focuses on providing innovative products for patients requiring respiratory therapy, making it a key player in the orthopedic, prosthetic, and surgical appliances industry. As of the latest filing, the company is classified as an accelerated filer and a smaller reporting company.

According to the recent SEC filing (accession number 0001294133-26-000047), Smith entered into a separation agreement with Inogen that outlines severance benefits, including eligibility for a prorated annual bonus for fiscal 2026 based on performance and vesting of certain equity awards scheduled to vest on December 1, 2026. This agreement reflects the company's commitment to providing support to departing executives.

Following Smith's resignation, the board of directors has been reduced from nine to eight members, effective November 17, 2026. The company has not specified what steps it will take next regarding board appointments or leadership restructuring.

This transition may have implications for Inogen's strategic direction and operational focus as it adapts to new leadership dynamics. The orthopedic, prosthetic, and surgical appliances industry may also observe shifts as competitors respond to these changes within Inogen.

Details regarding future filings or additional board appointments were not disclosed in the filing.